1 / 26

Prof. Francesco Violi

APS. Prof. Francesco Violi. Università degli Studi di Roma “La Sapienza”. APS (Antiphospholipid syndrome). Definition Clinical manifestations: a) venous and arterial thrombosis and foetal loss b) bleeding disorders Mechanism of disease Management. The Antiphospholipid Syndrome.

kelli
Download Presentation

Prof. Francesco Violi

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. APS Prof. Francesco Violi Università degli Studi di Roma “La Sapienza”

  2. APS (Antiphospholipid syndrome) • Definition • Clinical manifestations: a) venous and arterial thrombosis and foetal loss b) bleeding disorders • Mechanism of disease • Management

  3. The Antiphospholipid Syndrome It’s a clinical syndrome with widespread arterial and venous thrombosis associated with antibodies directed against phospholipids. The disorder was classified as “primary” (PAPS), in absence of a concurrent autoimmune condition, such as systemic lupus erythematosus, and secondary (APS) in presence of another autoimmune disease. Features include stroke and transient ischaemic attack, coronary artery disease, livedo reticularis, pulmonary hypertension, and recurrent aborption. Minor features include labile hypertension, migraine, epilepsy, minor myelopathy,thrombocytaemia, hearth valve disease and ocular ischaemia.

  4. Preliminary Classification Criteria for Antiphospholipid Antibody Syndrome, as Proposed at an International Consensus Workshop, October, 1998 Clinical Criteria Vascular Thrombosis: One or more episodes of • Arterial, or • Venous, or • Small vessel thrombosis, in any tissue or organ, confirmed by imaging or Doppler studies or histopathology. For histopathologic confirmation, thrombosis should be present without significant evidence of inflammation in the vessel wall • Three or more unexplained consecutive miscarriages with anatomic, genetic or hormonal causes excluded or • One or more unexplained deaths of a morphologically normal fetus at or after the terth week of gestation with fetal morphology documented by ultrasound or by direct examination of the fetus or • One of more premature birtrhs of a morphologically normal neonate at or before the 34th week of gestation associated with severe preclampsia or severe placental insufficiency. Pregnancy morbidity: Lockshin Thromb Haemostas 82:641-648, 1999

  5. Preliminary Classification Criteria for Antiphospholipid Antibody Syndrome, as Proposed at an International Consensus Workshop, October, 1998 Laboratory Criteria Anticardiolipin antibody • IgG and/or IgM isotype present in • Medium or higher titer, • On two or more occasion, 6 weeks or more apart, and • Measured by standardized ELISA for 2Glycoprotein I-dependent anticardiolipin antibody Abnormality present in plasma on • Two or more occasions 6 weeks or more apart and • Detected according to the guidelines of the SSC subcommittee on lupus anticoagulant/phospholipid dependent antibodies in the following steps: • Demonstration of a prolonged phospholipid-dependent coagulation screening test (e.g., activated partial thromboplastin time) kaolin clotting time, dilute Russell viper venom time, dilute prothrombin time, and Textarian time • Failure to correct the prolonged screening test by mixing with normal platelet-poor plasma  Shortening or correction of the prolonged screening test by the addition of excess phospholipid.  Exclusion of other coagulopathies as clinically indicated (e.g., factor VIII inhibitor) and heparin Lupus anticoagulant Lockshin Thromb Haemostas 82:641-648, 1999

  6. Prevalence of antiphospholipid antibody in various pregnancy series NORMAL PREGNANCY Lockshin Thrombosis and Haemostasis 82:641-648, 1999

  7. Prevalence of antiphospholipid antibody in various pregnancy series RECURRENT ABORTION Lockshin Thromb Haemostas 82:641-648, 1999

  8. Bleeding Disorder in APA Patients • Rare • Hypoprothrombinemia (20%) and piastrinopenia • Corticosteroid Treatment

  9. APS (Antiphospholipid syndrome) • Definition • Clinical manifestations: a) venous and arterial thrombosis and foetal loss b) bleeding disorders • Mechanism of disease • Management

  10. Mainantigenic Targets Of Antiphospholipid Antibodies (Apl)(React With Antigenic Epitopes In Phospholipid-protein Complexes) OXIDIZED LOW DENSITY LIPOPROTEIN (LDL) The major antigenic epitopes are induced in apolipoprotein B during oxidative modification of LDL. ANIONIC PHOSPHOLIPIDS (Cardiolipin Phosphatidylserine) Annexin V has potent anticoagulant properties in vitro, based on its high affinity for anionic phospholipids and its capacity to displace coagulation factors from phospholipids surface. aPL IgG fractions reduce the quantity of Annexin V in cultured throphoblast and endothelial cells and accelerate the coagulation of plasma incubated with the cells. The hypothesis is that Annexin V plays a thrombomodulatory apical role on the surface of cells lining the placental and systemic vasculatures. PROTHROMBIN (to allow proper immune recognition, must be adsorbed on suitable anionic surface). The majority of anti-prothrombin antibodies display lupus anticoagulant activity. PLASMA PHOSPHOLIPID-BINDING PROTEINS 2-Glycoprotein I (2GPI) is the most common and well-characterized antigenic target; aPL preferentially bind 2GPI that has immobilized on anionic phospholipid membrane.

  11. APS: Mechanism of disease • Experimental studies in animals • In vitro and ex vivo studies: a) endothelial cell b) monocytes c) platelets

  12. Dynamics of thrombus formation in immunized mice Time min Values are mean  SD * Statistically significant difference from control. Differences between the means of the 2GP1 and IgG-APS groups were not statistically significant Pierangeli et al. Circulation 94:1746-1751; 1996.

  13. APS: Mechanism of disease • Experimental studies in animals • In vitro and ex vivo studies: a) endothelial cell b) monocytes c) platelets

  14. Rand et al. N Engl J Med 337:154-60, 1997

  15. Monocyte O2· OH · Native Cardiolipin Rearrangement Oxidised Cardiolipin Antibodies against oxidised cardiolipin

  16. Praticò et al. Blood 93:3401-3407, 1999

  17. APS (Antiphospholipid syndrome) • Definition • Clinical manifestations: a) venous and arterial thrombosis and foetal loss b) bleeding disorders • Mechanism of disease • Management

  18. Randomized Controlled Trials of Treatment for Recurrent Fetal Loss in Women with Antiphospholipid Antibody *Marked increase in fetal and maternal morbidity compared to regimen A. ASA=acetyl salicylic acid Lockshin Thrombos Haemostas 82:641-648, 1999

  19. Patients Free of Thrombosis (%) Years Khamashta MA et al. N Engl J Med 332:993-7, 1995

  20. Crowther MA et al. N Engl J Med 2003

  21. Andrè et al – Circulation. 2002

  22. Andrè et al – Circulation. 2002

  23. aPL-negative aPL-positive patients (n=16) patients (n=14) p value Age (years), Mean ± SD 35±9 39±12 n.s. Range 18-54 20-56 n.s. Male sex (n) (%) 2 (13) 1 (7) n.s. Diabetes Mellitus (n) (%) 5 (31) 5 (35) n.s. Hypertension (n) (%) 6 (37) 5 (35) n.s. Smoking (n) (%) 6 (37) 4 (29) n.s. Platelet count / mm3191000±52000 212000±49000 n.s. Disease Activity: SLEDAI score Low disease activity (n) (%) 11 (69) 10 (71) n.s. (score 2-9) High disease activity (n) (%) 5 (31) 4 (29) n.s. (score _10) Arth. Rheum. (in press)

  24. Arth. Rheum. (in press)

  25. Arth. Rheum. (in press)

More Related